Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: ion channel and GABA A modulators - Saniona

Drug Profile

Research programme: ion channel and GABA A modulators - Saniona

Alternative Names: AN 346; AN 363; AN 470; AN 761; AN-726; NS9283; NSD-708; NSD-761; NSD-847; NSD-867; SAN 711

Latest Information Update: 22 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; NeuroSearch
  • Developer Saniona
  • Class Analgesics; Anti-inflammatories; Antidementias; Antipruritics; Neuroprotectants
  • Mechanism of Action Alpha4beta2 nicotinic receptor modulators; Alpha7 nicotinic acetylcholine receptor agonists; GABA A alpha 2 receptor modulators; GABA A alpha 3 receptor modulators; GABA A receptor modulators; GABA modulators; Intermediate conductance calcium activated potassium channel modulators; Ion channel modulators; Small conductance calcium activated potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; CNS disorders; Dyskinesias; Inflammatory bowel diseases; Neuropathic pain; Pruritus; Schizophrenia

Most Recent Events

  • 18 Feb 2019 Saniona plans a phase I trial for for SAN 711 during Summer 2019
  • 05 Dec 2017 Development of ion channel and GABA A modulators for CNS disorders, Dyskinesia, Inflammatory bowel disease and Neuropathic pain is ongoing Denmark
  • 04 Nov 2017 No recent reports of development identified for preclinical development in CNS-disorders in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top